Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Merkel

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Annals of the Rheumatic Diseases|June 25, 2016
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisM Yates, R A Watts, I M Bajema, et al.
Arthritis and Rheumatism|April 25, 2001
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)J H Stone, G S Hoffman, P A Merkel, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Clinical and Experimental Rheumatology|May 29, 2015
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohortsC Pagnoux, S Carette, N A Khalidi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitisE M Miloslavsky, U Specks, P A Merkel, et al.
Arthritis and Rheumatism|June 12, 2013
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitisE M Miloslavsky, U Specks, P A Merkel, et al.
Arthritis and Rheumatism|October 10, 2012
2012 revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesJ C Jennette, R J Falk, P A Bacon, et al.
Nature|June 5, 2024
A disease-associated gene desert directs macrophage inflammation through ETS2C T Stankey, C Bourges, L M Haag, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Arthritis and Rheumatism|December 14, 2004
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistJ H Korn, M Mayes, M Matucci Cerinic, et al.
Annals of the Rheumatic Diseases|June 25, 2016
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisM Yates, R A Watts, I M Bajema, et al.
Arthritis and Rheumatism|April 25, 2001
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)J H Stone, G S Hoffman, P A Merkel, et al.
Arthritis and Rheumatism|April 29, 1998
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind studyF M Wigley, J H Korn, M E Csuka, et al.
Clinical and Experimental Rheumatology|May 29, 2015
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohortsC Pagnoux, S Carette, N A Khalidi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitisE M Miloslavsky, U Specks, P A Merkel, et al.
Arthritis and Rheumatism|June 12, 2013
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitisE M Miloslavsky, U Specks, P A Merkel, et al.
Arthritis and Rheumatism|October 10, 2012
2012 revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesJ C Jennette, R J Falk, P A Bacon, et al.
Nature|June 5, 2024
A disease-associated gene desert directs macrophage inflammation through ETS2C T Stankey, C Bourges, L M Haag, et al.
Pageof 5